Two-Year Evaluation of Anti-retroviral Medicines Availability and Utilization in Supported Health Facilities in Osun State

Background: Antiretroviral (ARV) drugs have reduced the burden of human immune-deficiency virus globally availability of these medicines and adherence to treatment guideline are crucial in sustaining the control of the infection. This study aims to evaluate the availability and use of ARV medicines in supported health facilities in Osun State over 2 years. Methods: Combined Report and Requisition Forms of antiretroviral medicines prepared and transmitted, via e-mail to the State Logistics Management Coordinating Unit, between January 2017 and December 2018 from the HIV clinics of supported health facilities were reviewed. The collated data were analyzed using Microsoft Excel® software package. Results: Patients that were on ARV medicines in the period was 3555.9 ± 1170.35 (100%). The patients were comprised of 3068.4 ± 846.02 (86.29%) and 107.7 ± 87.31 (3.03%) adults on first and second-line ARV medicines respectively. The paediatrics on first and second-line ARV medicines were 195.3±123.25 (5.49%) and 14.2±12.19 (0.40%) respectively. Tenofovir/lamivudine/efavirenz (TDF/3TC/EFV) was the most commonly ordered, supplied and consumed drug regimen, followed by Zidovudine/lamivudine/ nevirapine (AZT/3TC/NVP). The adult first line fixed dose combinations were mostly ordered, supplied and consumed (85.63%, 85.38%, 85.83%), followed by paediatric first line fixed combinations (7.84%, 8.04%, 8.09%) and then adult second-line components (2.72%, 2.81%, 2.65%). The overall performance was 101.1%. Conclusion: ARV medicines used for patients in this study are in line with recommended standards. The first line ARV combination regimens (Tenofovir/lamivudine/efavirenz) were the most commonly ordered, supplied and consumed for both adults and paediatric populations.